Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation

Transplantation Proceedings

Volumn 42, Issue 9, 2010, Pages 3723-3728

  Hong, J Y ^a,b   Choi, M K ^a   Kim, D H ^a   Kim, S J ^a   Kim, K ^a   Kim, W S ^a   Chung, C W ^a   Kim, H O ^b   Min, Y H ^b   Jang, J H ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; CYCLOSPORIN; FLUDARABINE; GANCICLOVIR; MELPHALAN; METHOTREXATE; NYSTATIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIFUNGAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANDIDIASIS; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; ENGRAFTMENT; FEASIBILITY STUDY; FEMALE; FEVER; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HERPES VIRUS INFECTION; HUMAN; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; MALE; MORTALITY; MULTIPLE MYELOMA; NEUTROPHIL; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RECURRENT CANCER; REDUCED INTENSITY CONDITIONING; REPEAT PROCEDURE; SURVIVAL RATE; THROMBOCYTE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT PLANNING;

ADULT; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, NON-HODGKIN; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; MYELOABLATIVE AGONISTS; RECURRENCE; REOPERATION; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT FAILURE; VIDARABINE;

EID: 78649456158     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.09.005     Document Type: Article

References (21)

1. J.O. Armitage Bone marrow transplantation N Engl J Med 330 1994 827
2. O. Ringden, M.M. Horowitz, and R.P. Gale Outcome after allogeneic bone marrow transplant for leukemia in older adults JAMA 270 1993 57
3. E.P. Alyea, H.T. Kim, and V. Ho Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age Blood 105 2005 1810
4. M.L. Sorror, M.B. Maris, and B. Storer Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities Blood 104 2004 961
5. D. Valcarcel, R. Martino, and A. Sureda Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies Eur J Haematol 74 2005 144
6. B. Oran, S. Giralt, and R. Saliba Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan Biol Blood Marrow Transplant 13 2007 454
7. S. Giralt, P.F. Thall, and I. Khouri Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation Blood 97 2001 631
8. S. Giralt, A. Aleman, and A. Anagnostopoulos Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma Bone Marrow Transplant 30 2002 367
9. H. Glucksberg, R. Storb, and A. Fefer Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors Transplantation 18 1974 295
10. M. Sakiyama, M. Kami, and A. Hori Regimen-related toxicity following reduced-intensity stem-cell transplantation (RIST): comparison between Seattle criteria and National Cancer Center Common Toxicity Criteria (NCI-CTC) version 2.0 Bone Marrow Transplant 34 2004 787
11. P.A. McSweeney, D. Niederwieser, and J.A. Shizuru Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects Blood 97 2001 3390
12. R. Champlin, I. Khouri, and A. Shimoni Harnessing graft-versus- malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy Br J Haematol 111 2000 18
13. K.J. Thomson, K.S. Peggs, and P. Smith Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation Bone Marrow Transplant 41 2008 765
14. C. Grullich, H. Bertz, and A. Spyridonidis A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation Bone Marrow Transplant 41 2008 845
15. L.C. Feinstein, B.M. Sandmaier, and D.G. Maloney Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant Biol Blood Marrow Transplant 9 2003 266
16. J.L. Harousseau, M. Attal, and M. Divine Autologous stem cell transplantation after first remission induction treatment in multiple myeloma A report of the French Registry on Autologous Transplantation in Multiple Myeloma Stem Cells 13 suppl 2 1995 132
17. M. Attal, J.L. Harousseau, and A.M. Stoppa ntergroupe Francais du Myelome: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma N Engl J Med 335 1996 91
18. D.H. Vesole, G. Tricot, and S. Jagannath Autotransplants in multiple myeloma: what have we learned? Blood 88 1996 838
19. B.B. Bjorkstrand, P. Ljungman, and H. Svensson Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation Blood 88 1996 4711
20. J.M. Vose, P.J. Bierman, and J.R. Anderson Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up Blood 80 1992 2142
21. M. Varterasian, V. Ratanatharathorn, and J.P. Uberti Clinical course and outcome of patients with Hodgkin's disease who progress after autologous transplantation Leuk Lymphoma 20 1995 59